1. Microphysiological systems, or “Body-on-a-Chip” devices, have been proposed as in vitro systems to improve drug discovery and reduce dependency on animal studies in preclinical testing.
2. Various computer/mathematical models have been designed to improve the study of physiologically based pharmacokinetic–pharmacodynamics (PBPK–PD) based drug toxicity, mimic some multi-organ interactions and simulate parts of human metabolism.
3. This paper describes a “pumpless” platform system that allowed for at least 14 chambers representing 13 different cell/tissue types or organs, designed by considering a number of factors such as the PBPK model and overall physical device size.
The article is generally reliable and trustworthy, providing an overview of microphysiological systems and their potential applications in drug discovery and preclinical testing. The article is well researched and provides evidence for its claims, such as citing various studies that have used 3D cell culture models to better mimic organ metabolism compared to monolayer cultures. The article also provides a detailed description of the design process for the pumpless 14 chamber device, including considerations such as the PBPK model and overall physical device size.
The article does not appear to be biased or one-sided in its reporting, presenting both sides equally with no promotional content or partiality. It also notes possible risks associated with using these systems, such as the fact that they may not always predict the human response to drugs or chemicals accurately.
The only potential issue with this article is that it does not explore any counterarguments or missing points of consideration regarding microphysiological systems and their applications in drug discovery and preclinical testing. However, this does not detract from its overall reliability and trustworthiness as an informative source on this topic.